Soluble CD14 as a Diagnostic Biomarker for Smear-Negative HIV-Associated Tuberculosis

Liu, Yanyan; Ndumnego, Okechukwu Chinazo; Chen, Tingting; Kim, Ryung S.; Jenny-Avital, Elizabeth R.; Ndung’u, Thumbi; Wilson, Douglas P.; Achkar, Jacqueline M.

doi:10.3390/pathogens7010026

Cited by 16 publications

(14 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that personalized, comprehensive intervention measures can significantly improve the sputumnegative conversion rate of smear-positive pulmonary tuberculosis patients. In the case management mode of newly treated smear-positive pulmonary tuberculosis patients, the case management team continuously evaluates, treats, and nurses patients; after discharge, the case management team carries out regular telephone and outpatient follow-ups and conducts real-time monitoring and tracking on the follow-ups to improve patients' treatment compliance and the sputumnegative conversion rate of newly treated smearpositive pulmonary tuberculosis patients [17][18][19][20][21][22].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of a case management model in newly treated smear-positive pulmonary tuberculosis patients

Wang

et al. 2021

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: To investigate the effectiveness of the case management mode on the application of smear-positive pulmonary tuberculosis patients. Methodology: This was a randomized control trial. A total of 70 newly diagnosed smear-positive pulmonary tuberculosis patients were recruited and been randomly divided into experimental group and control group, with 35 participants in each group. In the experimental group, patients received the tuberculosis case management mode based on the conventional management mode. In the control group, patients received the routine management mode. We compared the knowledge, attitude, and practice score; sputum-negative conversion rate, effective imaging rate of the two groups at the time of initial admission, discharge, and one month after discharge. Results: The results showed that there was no significant difference in baseline data between the two groups (p > 0.05); at the time of discharge and one month after discharge, the knowledge, belief, behavior, sputum-negative conversion rate, and imaging examination effective rate of the experimental group were higher than those of the control group (p < 0.05). Conclusions: The case management mode can improve the knowledge, attitude, and practice level; sputum-negative conversion rate; and imaging efficiency of newly treated smear-positive pulmonary tuberculosis patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of a case management model in newly treated smear-positive pulmonary tuberculosis patients

Wang

et al. 2021

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Increase in TGF-b3 prior to TB recurrence likely reflects the increase in systemic inflammation. Additionally, TGF-b1 and TGF-b2 expression was positively correlated with sCD14 expression, a known marker of active TB (11,18,41,42). While there is a general lack of isoform-specific data on TGF-b, isoform -specific knockout mice studies have shown non-redundant phenotypes.…”

Section: Discussionmentioning

confidence: 99%

Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa

et al. 2021

View full text Add to dashboard Cite

There is an urgent need to identify immunological markers of tuberculosis (TB) risk in HIV co-infected individuals. Previously we have shown that TB recurrence in HIV co-infected individuals on ART was associated with markers of systemic inflammation (IL-6, IL1β and IL-1Rα). Here we examined the effect of additional acute inflammation and microbial translocation marker expression on risk of TB recurrence. Stored plasma samples were drawn from the TB Recurrence upon Treatment with HAART (TRuTH) study, in which individuals with previously treated pulmonary TB were screened for recurrence quarterly for up to 4 years. Recurrent TB cases (n = 37) were matched to controls (n = 102) by original trial study arm assignment and ART start date. Additional subsets of HIV infected (n = 41) and HIV uninfected (n = 37) individuals from Improving Recurrence Success (IMPRESS) study were sampled at active TB and post successful treatment completion. Plasma concentrations of soluble adhesion molecules (sMAdCAM, sICAM and sVCAM), lipopolysaccharide binding protein (LBP) and transforming growth factor-beta (TGF-β1, TGF-β2, TGF-β3) were measured by multiplex immunoassays and ELISA. Cytokine data was square root transformed in order to reduce variability. Multivariable analysis adjusted for a number of potential confounders measured at sample time-point: age, BMI, CD4 count, viral load (VL) and measured at baseline: presence or absence of lung cavities, previous history of TB, and WHO disease stage (4 vs 3). The following analytes were associated with increased risk of TB recurrence in the multivariable model: sICAM (aOR 1.06, 95% CI: 1.02-1.12, p = 0.009), LBP (aOR 8.78, 95% CI: 1.23-62.66, p = 0.030) and TGF-β3 (aOR 1.44, 95% CI 1.01-2.05, p = 0.044). Additionally, we observed a positive correlation between LBP and sICAM (r= 0.347, p<0.0001), and LBP and IL-6, identified to be one of the strongest predictors of TB risk in our previous study (r=0.623, p=0.03). These data show that increased risk of TB recurrence in HIV infected individuals on ART is likely associated with HIV mediated translocation of microbial products and the resulting chronic immune activation.

show abstract

“…Compared with the HC group, the sCD14 abundance was significantly up‐regulated in the DS‐TB group and the MDR‐TB group, but the sCD14 abundance in the MDR‐TB group was lower than that in the DS‐TB group. Studies have reported that the sCD14 may serve as a potential biomarker for TB, 16 but there is no study available regarding the role of sCD14 in the progression of TB. The sCD14 protein is an indicator of monocyte activation 17 .…”

Section: Discussionmentioning

confidence: 99%

Serum sCD14, PGLYRP2 and FGA as potential biomarkers for multidrug‐resistant tuberculosis based on data‐independent acquisition and targeted proteomics

Chen

Han

Wang

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Multidrug-resistant tuberculosis (MDR-TB) is a subtype of tuberculosis (TB) that is resistant to at least isoniazid and rifampicin. It requires long-term (18-24 months) treatment, in which second-line drugs are less effective and can cause adverse reactions. 1 Although worldwide the diagnosis and treatment of TB have been improved in recent years, leading to a decreasing trend in the overall incidence of tuberculosis, MDR-TB is still a major global concern. China is a high MDR-TB burden country. There are various causes of MDR-TB infection, for example infection with resistant strains of Mycobacterium tuberculosis (MTB) and unfavourable duration of treatment with

show abstract

Soluble CD14 as a Diagnostic Biomarker for Smear-Negative HIV-Associated Tuberculosis

Cited by 16 publications

References 64 publications

Effectiveness of a case management model in newly treated smear-positive pulmonary tuberculosis patients

Effectiveness of a case management model in newly treated smear-positive pulmonary tuberculosis patients

Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa

Serum sCD14, PGLYRP2 and FGA as potential biomarkers for multidrug‐resistant tuberculosis based on data‐independent acquisition and targeted proteomics

Contact Info

Product

Resources

About